Seeking Alpha

Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform...

Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals.
From other sites
Comments (1)
  • A SMARTER GREEK
    , contributor
    Comments (20) | Send Message
     
    Mr. Duggan the CEO and Chairman..is repeating again with a phenominlal product(s), and successfull company in PCYC as he did
    with ISRG..from 12 to 500!
    Real company, great products, good management..de ja vu!
    13 May 2013, 01:17 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs